Phospho-ANXA2 (S26) Antibody

What is the specificity of Phospho-ANXA2 (S26) antibodies and how should I validate it?

Phospho-ANXA2 (S26) antibodies are designed to detect Annexin A2 protein only when phosphorylated at the Serine 26 position. To validate specificity:

• Control experiments: Always include non-phosphorylated ANXA2 controls alongside phosphorylated samples

• Phosphatase treatment: Treat a portion of your sample with lambda phosphatase to confirm signal loss

• Peptide competition assay: Pre-incubate antibody with phospho-S26 peptide; signal should decrease significantly

• Cross-reactivity assessment: Test against closely related Annexin family members

The antibody is typically generated using a synthesized phospho-peptide around the S26 site of human Annexin II conjugated to KLH or another carrier protein . Most commercial Phospho-ANXA2 (S26) antibodies demonstrate reactivity with human, mouse, and rat samples, making them versatile for cross-species studies .

What are the recommended applications and dilutions for Phospho-ANXA2 (S26) antibodies?

Based on validated data from multiple sources, Phospho-ANXA2 (S26) antibodies perform optimally in:

For Western blot applications:

• Use PVDF membrane for optimal results

• Block with 5% BSA rather than milk (phospho-epitopes can be masked by casein)

• Include phosphatase inhibitors in all buffers

• Expected molecular weight: ~38.6 kDa

These antibodies are typically formulated as liquid in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide .

How should I store and handle Phospho-ANXA2 (S26) antibody to maintain its activity?

Proper storage and handling are crucial for maintaining antibody performance:

• Long-term storage: Store at -20°C for up to one year

• Short-term/frequent use: Store at 4°C for up to one month

• Avoid freeze-thaw cycles: Aliquot upon first thaw to minimize degradation

• Working solution preparation: Dilute only what you need in fresh buffer containing 1% BSA

• Stability considerations: The antibody formulation (50% glycerol, 0.5% BSA, 0.02% sodium azide) helps maintain stability, but repeated temperature fluctuations will still reduce activity

For experiments requiring maximum sensitivity, use freshly thawed aliquots. When handling for immunoblotting, maintain phosphatase inhibitors in lysis buffers and sample preparation to preserve phosphorylation states .

What is the functional significance of ANXA2 phosphorylation at Serine 26?

The S26 phosphorylation site of ANXA2 has significant structural and functional implications:

• Structural role: S26 is positioned at a critical junction between Domains I and IV of ANXA2, where it inserts between these domains along with V27

• Protein folding effects: This region (including G25-D34) is crucial for the autonomous folding and stability of Domain I of ANXA2

• Velcro-like function: The region containing S26 acts as a bridging segment that stabilizes the core structure, similar to its function in other annexins

• Interaction with calcium binding: Phosphorylation at S26 may modulate calcium-dependent membrane binding properties of ANXA2

Interestingly, while mutations in this region can disrupt the autonomous folding of Domain I, they don't necessarily abolish folding of the full-length protein, suggesting a complex role in ANXA2 structure and function . The phosphorylation status at S26 likely regulates protein-protein interactions and subcellular localization of ANXA2.

How does ANXA2 phosphorylation differ between normal and pathological conditions?

ANXA2 phosphorylation states change significantly in various pathological conditions:

• Cardiovascular disease: During oscillatory shear stress (OSS) conditions that promote atherosclerosis, ANXA2 undergoes dephosphorylation at Y24 through a Piezo1-Ca²⁺-PTP1B cascade, which leads to conformational change and binding with integrin α5

• Pulmonary fibrosis: In bleomycin-induced pulmonary fibrosis, ANXA2 acts as a specific target of bleomycin, though the direct effect on S26 phosphorylation requires further investigation

• Cancer: Altered phosphorylation of ANXA2 has been implicated in cancer progression, though most studies have focused on other phosphorylation sites

The mechanistic connection between S26 phosphorylation and Y24 dephosphorylation remains an important area for investigation. Current evidence suggests a coordinated regulation of multiple phosphorylation sites that collectively determine ANXA2 function in different cellular contexts .

How does phosphorylation at S26 affect ANXA2's interaction with binding partners?

The phosphorylation of ANXA2 at S26 modulates its interactions with various binding partners:

• Membrane association: Phosphorylation likely influences ANXA2's calcium-dependent membrane binding properties, as S26 is positioned near the calcium-binding regions

• p11 (S100A10) binding: The S26 site is near the N-terminal region involved in p11 binding, which forms the heterotetrameric calpactin I complex

• Integrin interactions: While Y24 dephosphorylation is directly implicated in integrin α5 binding, S26 phosphorylation may work coordinately to regulate these interactions

• Lipid raft association: Phosphorylation state influences ANXA2 translocation to lipid rafts, which is crucial for many of its cellular functions

Methodologically, researchers can use co-immunoprecipitation with Phospho-ANXA2 (S26) antibodies to identify phosphorylation-dependent binding partners, comparing results with non-phosphorylated ANXA2 immunoprecipitation to distinguish specific interactions .

What are the best experimental approaches to study dynamic changes in ANXA2 S26 phosphorylation?

To effectively monitor dynamic changes in ANXA2 S26 phosphorylation:

• Time-course studies:

  • Treat cells with stimuli known to affect ANXA2 (calcium ionophores, shear stress, growth factors)

  • Collect samples at multiple time points (0, 5, 15, 30, 60 minutes)

  • Analyze by Western blot with phospho-specific and total ANXA2 antibodies

• Phosphorylation site mutants:

  • Generate S26A (phospho-null) and S26D/E (phosphomimetic) mutants

  • Express in ANXA2-knockout cells to study functional consequences

  • Compare cellular localization and binding partner interactions

• Mass spectrometry approaches:

  • Immunoprecipitate ANXA2 from stimulated cells

  • Analyze by LC-MS/MS for quantitative assessment of phosphorylation

  • Use SILAC or TMT labeling for comparative analysis across conditions

• Live-cell imaging:

  • Develop phospho-specific biosensors using FRET technology

  • Monitor real-time changes in phosphorylation in response to stimuli

  • Correlate with subcellular localization changes

Remember that preserving phosphorylation states requires rapid sample processing and inclusion of phosphatase inhibitors in all buffers .

How can I optimize immunoprecipitation protocols for Phospho-ANXA2 (S26) detection?

For successful immunoprecipitation of phosphorylated ANXA2:

• Lysis buffer optimization:

  • Use RIPA or NP-40 buffer supplemented with:

    • Phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate)

    • Protease inhibitors (PMSF, leupeptin, aprotinin)

    • EDTA to chelate calcium (prevents calcium-dependent membrane binding)

• Antibody selection and incubation:

  • Pre-clear lysate with protein A/G beads (1 hour at 4°C)

  • Use 2-5 μg antibody per 500 μg protein

  • Incubate overnight at 4°C with gentle rotation

  • Add protein A/G beads for 2-3 hours

• Washing conditions:

  • Use gentler washing to preserve phospho-epitopes

  • Perform 4-5 washes with lysis buffer containing reduced detergent

  • Maintain phosphatase inhibitors in wash buffers

• Elution and detection:

  • Elute with 2X SDS sample buffer without boiling (65°C for 5 minutes)

  • Analyze by Western blot with phospho-specific and total ANXA2 antibodies

  • Consider comparing results with non-phospho-specific ANXA2 antibodies

What are the methodological considerations when studying ANXA2 S26 phosphorylation in tissues versus cell lines?

Key methodological differences for analyzing ANXA2 phosphorylation in tissues versus cell lines:

For tissues:

• Sample preservation:

  • Flash-freeze tissues immediately after collection

  • Consider phosphatase inhibitor perfusion for optimal preservation

  • Process samples quickly to minimize phospho-epitope loss

• Extraction methods:

  • Use a dounce homogenizer with RIPA buffer containing higher concentrations of phosphatase inhibitors

  • Perform extraction at 4°C throughout

  • Centrifuge at higher speeds (15,000-20,000 × g) to remove debris

• Background reduction:

  • Implement more stringent blocking (5% BSA + 0.5% casein)

  • Use tissue-specific validated antibody dilutions (generally more concentrated than for cell lines)

  • Consider antigen retrieval methods for fixed tissue sections

For cell lines:

• Stimulation protocols:

  • Standardize serum starvation periods (16-24 hours)

  • Optimize stimulation times specifically for ANXA2 phosphorylation

  • Include positive controls (e.g., calcium ionophores)

• Detection sensitivity:

  • Cell lines often show cleaner backgrounds

  • Can use more dilute antibody concentrations

  • Consider enrichment by phosphoprotein purification columns

• Quantification approaches:

  • Always normalize phospho-signal to total ANXA2 levels

  • Use fluorescent secondary antibodies for wider dynamic range

  • Include loading controls appropriate for subcellular fraction being analyzed

How can Phospho-ANXA2 (S26) antibodies be applied in atherosclerosis research?

Phospho-ANXA2 (S26) antibodies offer valuable tools for atherosclerosis research:

• Mechanistic studies of flow-dependent endothelial activation:

  • Research has shown that oscillatory shear stress (OSS) induces dephosphorylation of ANXA2 at Y24, leading to conformational changes and binding with integrin α5

  • Phospho-ANXA2 antibodies can track this process and its relationship to S26 phosphorylation

  • Compare regions of disturbed flow versus laminar flow in vessel studies

• Disease progression monitoring:

  • Analyze ANXA2 phosphorylation status in:

    • Atheroprone regions of vessels

    • Early versus advanced atherosclerotic lesions

    • Animal models before and after interventions

• Therapeutic target validation:

  • Screen compounds that modulate ANXA2 phosphorylation

  • Correlate phosphorylation changes with endothelial activation markers

  • Assess ANXA2 phosphorylation in response to statins or other treatments

• Methodological approach:

  • Immunohistochemistry of vessel sections with phospho-specific antibodies

  • Flow studies in cultured endothelial cells with real-time monitoring

  • Co-localization with lipid raft markers and integrin α5

  • Correlate with markers of endothelial dysfunction

What are the optimal controls when using Phospho-ANXA2 (S26) antibodies in experimental design?

Robust experimental design requires appropriate controls when using Phospho-ANXA2 (S26) antibodies:

• Positive controls:

  • Recombinant phosphorylated ANXA2 peptide or protein

  • Cell lines with known high levels of S26 phosphorylation (e.g., stimulated endothelial cells)

  • Tissues with documented ANXA2 S26 phosphorylation

• Negative controls:

  • ANXA2 knockout cell lines

  • Samples treated with lambda phosphatase

  • Competing peptide blocking (pre-incubation of antibody with phospho-peptide)

  • S26A mutant-expressing cells

• Specificity controls:

  • Detection with secondary antibody only

  • Isotype control antibody

  • Cross-validation with a second phospho-specific antibody

  • Comparison with total ANXA2 antibody staining

• Treatment controls:

  • Time-course controls to establish baseline and peak phosphorylation

  • Dose-response to establish optimal conditions

  • Vehicle controls for all treatments

  • Positive control treatments known to induce phosphorylation (e.g., calcium ionophores)

How can researchers integrate Phospho-ANXA2 (S26) analysis with broader signaling pathway studies?

To effectively integrate Phospho-ANXA2 (S26) analysis into broader signaling studies:

• Multi-parameter analysis approaches:

  • Multiplex Western blotting with other phospho-proteins

  • Phospho-kinase arrays including ANXA2

  • Mass spectrometry-based phosphoproteomics

  • Single-cell phospho-flow cytometry for heterogeneous populations

• Pathway interaction studies:

  • Combine with calcium signaling measurements (ANXA2 is calcium-regulated)

  • Analyze relationship with integrin activation pathways

  • Examine correlation with tyrosine phosphorylation at Y24

  • Study connection to Piezo1-Ca²⁺-PTP1B signaling cascade

• Systems biology integration:

  • Temporal analysis of phosphorylation events (kinetic studies)

  • Mathematical modeling of ANXA2 phosphorylation dynamics

  • Network analysis incorporating known ANXA2 interactions

  • Correlation with transcriptomic and proteomic datasets

• Functional readouts to connect with downstream effects:

  • Membrane trafficking assays

  • Cellular adhesion measurements

  • Migration and invasion assays

  • Lipid raft isolation and analysis

By integrating these approaches, researchers can position ANXA2 S26 phosphorylation in its proper cellular context and understand both its upstream regulators and downstream effectors .

What are the most common issues when detecting Phospho-ANXA2 (S26) and how can they be resolved?

Researchers commonly encounter these challenges when working with Phospho-ANXA2 (S26) antibodies:

• Weak or absent signal:

  • Problem: Degradation of phospho-epitope during sample preparation

  • Solution: Add phosphatase inhibitors to all buffers; process samples quickly; maintain low temperature throughout

  • Alternative approach: Enrich phosphoproteins before Western blotting

• High background:

  • Problem: Non-specific binding of antibody

  • Solution: Optimize blocking (5% BSA is preferred over milk); increase washing steps; titrate antibody concentration; use alternative membrane

  • Alternative approach: Try different detection system or more specific secondary antibodies

• Multiple bands or incorrect molecular weight:

  • Problem: Detection of degradation products or cross-reactivity

  • Solution: Use fresher samples; include protease inhibitors; verify with second antibody

  • Alternative approach: Perform immunoprecipitation followed by Western blot with total ANXA2 antibody

• Inconsistent results between experiments:

  • Problem: Variable phosphorylation status or unstable antibody

  • Solution: Standardize cell treatment protocols; use internal controls; aliquot antibody to avoid freeze-thaw cycles

  • Alternative approach: Consider alternative detection methods like ELISA or phospho-flow cytometry

How can I distinguish between specific Phospho-ANXA2 (S26) signal and artifacts in my experimental system?

To distinguish genuine phospho-specific signal from artifacts:

• Validation through multiple approaches:

  • Confirm key findings with at least two detection methods (e.g., Western blot and immunofluorescence)

  • Use alternative antibodies targeting the same phospho-site if available

  • Verify with mass spectrometry analysis of immunoprecipitated ANXA2

• Specific controls for phosphorylation:

  • Compare samples treated with lambda phosphatase

  • Use phosphatase inhibitors versus no inhibitors during sample preparation

  • Test S26A mutant-expressing cells alongside wild-type

• Signal specificity tests:

  • Peptide competition assay (pre-incubate antibody with phospho-S26 peptide)

  • Immunodepleting with total ANXA2 antibody before probing with phospho-specific antibody

  • Dose-dependent signal change with treatments known to affect phosphorylation

• Cross-validation strategies:

  • Correlate Phospho-ANXA2 (S26) signal with activation of known upstream kinases

  • Compare results across multiple cell types or tissues

  • Use genetic approaches (knockdown/knockout) to confirm specificity

What approaches can resolve contradictory data when studying ANXA2 phosphorylation across different experimental systems?

When faced with contradictory data across experimental systems:

• Standardize experimental conditions:

  • Synchronize cell cycle stages (phosphorylation states vary throughout cell cycle)

  • Standardize cell density and passage number

  • Use consistent lysis and sample preparation protocols

  • Implement identical antibody concentrations and incubation conditions

• Consider context-dependent regulation:

  • Cell type-specific differences in ANXA2 phosphorylation pathways may exist

  • Microenvironment factors (ECM, cell-cell contacts) can influence phosphorylation

  • Baseline phosphorylation states may vary between model systems

  • Temporal dynamics of phosphorylation may differ across systems

• Analyze concurrent phosphorylation at multiple sites:

  • Examine potential interplay between S26 and Y24 phosphorylation

  • Consider hierarchical phosphorylation patterns

  • Test how mutations at one site affect phosphorylation at others

• Integrate multiple analytical techniques:

  • Combine biochemical approaches (Western blot) with imaging (immunofluorescence)

  • Supplement with functional assays to determine biological relevance

  • Use high-resolution techniques like FRET to measure interactions dependent on phosphorylation state

  • Employ systems biology approaches to integrate contradictory data points